Abbott Laboratories (ABT) Stock Price & Analysis
Abbott Laboratories (ABT) rose 2.29% to USD 103.06 as of July 25, 2026 at 01:13 UTC, according to Nexqual real-time market data.
ABT last closed at USD 100.75; the session ranged USD 101.55–104.18 on volume of 10,366,517 shares. Market capitalization is —, with a 52-week range of USD 81.97–137.49 (NYQ). Source: Nexqual, July 25, 2026 at 01:13 UTC.
Key Statistics (as of July 25, 2026 at 01:13 UTC)
| Price | USD 103.06 |
|---|---|
| Change | ▲ 2.29% (up) |
| Previous Close | USD 100.75 |
| Open | USD 101.5 |
| Day Range | USD 101.55 – 104.18 |
| 52-Week Range | USD 81.97 – 137.49 |
| Volume | 10,366,517 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (ABT)
Nexqual's technical model rates ABT "BUY" based on 5 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 01:13 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 66.95 (neutral) |
| vs SMA50 | Above (USD 91.28) |
| MACD | 2.79 (positive) |
Analyst Ratings (ABT)
Wall Street analysts rate ABT "Buy" based on 24 analysts, with a mean price target of USD 119.13 (range USD 103–135), per Nexqual as of July 25, 2026 at 01:13 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 24 |
| Mean Target | USD 119.13 |
| High Target | USD 135 |
| Low Target | USD 103 |
| Buy / Hold / Sell | 20 / 7 / 0 |
Earnings (ABT)
| Next Earnings Date | 2026-10-14 |
|---|---|
| EPS Estimate | USD 1.42 |
| Revenue Estimate | $12.99B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.31 vs est 1.28 ▲ beat |
| 2026-03-31 | USD 1.15 vs est 1.15 ▲ beat |
| 2025-12-31 | USD 1.5 vs est 1.49 ▲ beat |
| 2025-09-30 | USD 1.3 vs est 1.3 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Financials & Fundamentals (ABT)
| Total Revenue | $46.58B |
|---|---|
| Revenue Growth (YoY) | +13.00% |
| Gross Margin | +56.77% |
| Operating Margin | +14.15% |
| Profit Margin | +11.65% |
| Debt / Equity | 64.77 |
| Total Cash | $7.30B |
| Total Debt | $34.14B |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Financial Health Score (ABT)
Nexqual rates Abbott Laboratories's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 01:13 UTC.
| Growth | Solid — Revenue +13% YoY (latest Q) |
|---|---|
| Profitability | Strong — Gross margin 57%, operating 14% |
| Balance Sheet | Solid — $7.30B cash vs $34.1B debt |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Ownership (ABT)
| Insider Ownership | +0.49% |
|---|---|
| Institutional Ownership | +82.46% |
| Float | 1.73B |
| Short % of Float | +1.50% |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Leadership (ABT)
Abbott Laboratories is led by Philip P. Boudreau (age 52), CFO & Executive VP of Finance, per Nexqual as of July 25, 2026 at 01:13 UTC.
| CFO & Executive VP of Finance | Philip P. Boudreau (age 52) |
|---|---|
| Executive VP and Group President of Established Pharmaceuticals & Nutritional Products | Daniel Gesua Sive Salvadori (age 46) |
| Executive Vice President of Diabetes Care | Christopher J. Scoggins (age 55) |
| Executive VP & Group President of Medical Devices | Lisa D. Earnhardt (age 55) |
Major Backers & Investors (ABT)
Notable institutional backers of Abbott Laboratories include Capital Group, Charles Schwab Investment Management, Inc., Capital International Investors, according to Nexqual as of July 25, 2026 at 01:13 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capital Group | 2.86% |
| Charles Schwab Investment Management, Inc. | 2.61% |
| Capital International Investors | 2.15% |
| Morgan Stanley | 1.73% |
| Wellington Management | 1.55% |
| Fidelity | 1.28% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 16.42% |
| BlackRock | 9.68% |
| State Street | 5.78% |
| Geode Capital | 2.25% |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
From Abbott Laboratories's Latest SEC 10-K Filing (filed 2026-02-20)
Key Strengths & Strategy (as disclosed to the SEC)
- Department of Health and Human Services has issued rules governing the use, disclosure, and security of protected health information, and the FDA has issued further guidance concerning cybersecurity for medical devices.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ABBV | AbbVie Inc. | USD 259.36 | ▲ 2.39% |
| BMY | Bristol-Myers Squibb Company | USD 62.09 | ▲ 2.19% |
| JNJ | Johnson & Johnson | USD 263.4 | ▲ 3.04% |
| MDT | Medtronic plc. | USD 83.21 | ▲ 1.61% |
| LLY | Eli Lilly and Company | USD 1,196.03 | ▲ 2.84% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:13 UTC. This page is informational and not investment advice.